NZ593086A - Isolated peptide binding to human leukocyte antigen (HLA) and having cytotoxic T lymphocyte (CTL) inducibility - Google Patents

Isolated peptide binding to human leukocyte antigen (HLA) and having cytotoxic T lymphocyte (CTL) inducibility

Info

Publication number
NZ593086A
NZ593086A NZ593086A NZ59308609A NZ593086A NZ 593086 A NZ593086 A NZ 593086A NZ 593086 A NZ593086 A NZ 593086A NZ 59308609 A NZ59308609 A NZ 59308609A NZ 593086 A NZ593086 A NZ 593086A
Authority
NZ
New Zealand
Prior art keywords
inducibility
ctl
lymphocyte
cytotoxic
hla
Prior art date
Application number
NZ593086A
Other languages
English (en)
Inventor
Takuya Tsunoda
Ryuji Ohsawa
Sachiko Yoshimura
Tomohisa Watanabe
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Priority to NZ605799A priority Critical patent/NZ605799A/en
Publication of NZ593086A publication Critical patent/NZ593086A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ593086A 2008-12-05 2009-12-03 Isolated peptide binding to human leukocyte antigen (HLA) and having cytotoxic T lymphocyte (CTL) inducibility NZ593086A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ605799A NZ605799A (en) 2008-12-05 2009-12-03 Wdrpuh epitope peptides and vaccines containing the same

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20096208P 2008-12-05 2008-12-05
US20970409P 2009-03-09 2009-03-09
PCT/JP2009/006573 WO2010064430A1 (en) 2008-12-05 2009-12-03 Wdrpuh epitope peptides and vaccines containing the same

Publications (1)

Publication Number Publication Date
NZ593086A true NZ593086A (en) 2013-02-22

Family

ID=42233088

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ593086A NZ593086A (en) 2008-12-05 2009-12-03 Isolated peptide binding to human leukocyte antigen (HLA) and having cytotoxic T lymphocyte (CTL) inducibility
NZ605799A NZ605799A (en) 2008-12-05 2009-12-03 Wdrpuh epitope peptides and vaccines containing the same

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ605799A NZ605799A (en) 2008-12-05 2009-12-03 Wdrpuh epitope peptides and vaccines containing the same

Country Status (18)

Country Link
US (3) US8541546B2 (cg-RX-API-DMAC7.html)
EP (3) EP2370454A4 (cg-RX-API-DMAC7.html)
JP (1) JP5764823B2 (cg-RX-API-DMAC7.html)
KR (1) KR101705102B1 (cg-RX-API-DMAC7.html)
CN (2) CN102307891B (cg-RX-API-DMAC7.html)
AU (1) AU2009323523B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0922844A2 (cg-RX-API-DMAC7.html)
CA (2) CA3031126C (cg-RX-API-DMAC7.html)
DK (1) DK3219720T3 (cg-RX-API-DMAC7.html)
ES (1) ES2913148T3 (cg-RX-API-DMAC7.html)
IL (2) IL212945B (cg-RX-API-DMAC7.html)
MX (1) MX2011005944A (cg-RX-API-DMAC7.html)
NZ (2) NZ593086A (cg-RX-API-DMAC7.html)
RU (1) RU2514386C2 (cg-RX-API-DMAC7.html)
SG (1) SG171977A1 (cg-RX-API-DMAC7.html)
TW (2) TWI539160B (cg-RX-API-DMAC7.html)
WO (1) WO2010064430A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201104890B (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140138900A (ko) 2012-03-09 2014-12-04 온코세라피 사이언스 가부시키가이샤 펩티드를 포함한 의약 조성물
JP6283861B2 (ja) 2012-09-11 2018-02-28 オンコセラピー・サイエンス株式会社 Ube2tペプチドおよびそれを含むワクチン

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5922687A (en) 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
EP0841945B1 (en) 1995-08-03 2006-03-08 Rijksuniversiteit te Leiden Cell derived antigen presenting vesicles
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
JP2000516090A (ja) 1996-07-26 2000-12-05 スローン―ケッタリング インスティチュート フォー キャンサー リサーチ 遺伝子的免疫化のための方法と試薬
FR2766205B1 (fr) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
AU749544B2 (en) 1998-06-25 2002-06-27 Dainippon Sumitomo Pharma Co., Ltd. Tumor antigen peptides originating in cyclophilin B
CN101613406A (zh) 2002-06-06 2009-12-30 肿瘤疗法科学股份有限公司 与人结肠癌相关的基因和多肽
WO2003104275A2 (en) 2002-06-06 2003-12-18 Oncotherapy Science, Inc. Genes and polypeptides relating to human colon cancers
EP2267023B1 (en) * 2002-09-12 2015-02-11 Oncotherapy Science, Inc. KDR peptides and vaccines comprising the same
WO2006031221A1 (en) 2004-09-13 2006-03-23 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Compositions comprising t cell receptors and methods of use thereof
DK2325306T3 (en) 2005-02-25 2014-03-03 Oncotherapy Science Inc Peptide vaccines against lung cancers expressing TTK, URLC10 or KOC1 polypeptide
CN101287831B (zh) 2005-09-13 2013-05-15 国立大学法人三重大学 T细胞受体和编码该受体的核酸
TWI494319B (zh) * 2007-02-21 2015-08-01 Oncotherapy Science Inc 表現腫瘤相關抗原之癌症的胜肽疫苗
TW201425333A (zh) * 2007-04-11 2014-07-01 Oncotherapy Science Inc 腫瘤血管內皮標誌8胜肽及包含此胜肽之疫苗
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same

Also Published As

Publication number Publication date
EP2370454A4 (en) 2013-11-20
EP4047009A2 (en) 2022-08-24
CN102307891B (zh) 2015-02-04
KR20110099018A (ko) 2011-09-05
EP2370454A1 (en) 2011-10-05
EP4047009A3 (en) 2022-11-16
BRPI0922844A2 (pt) 2015-12-29
TW201510529A (zh) 2015-03-16
RU2011127429A (ru) 2013-01-10
IL228266A (en) 2016-09-29
CA2745408C (en) 2019-03-12
ZA201104890B (en) 2012-03-28
KR101705102B1 (ko) 2017-02-22
JP5764823B2 (ja) 2015-08-19
JP2012510794A (ja) 2012-05-17
US20110293645A1 (en) 2011-12-01
RU2514386C2 (ru) 2014-04-27
TWI500932B (zh) 2015-09-21
US8541546B2 (en) 2013-09-24
NZ605799A (en) 2014-03-28
AU2009323523B2 (en) 2016-08-11
US9745343B2 (en) 2017-08-29
CA2745408A1 (en) 2010-06-10
TW201027074A (en) 2010-07-16
US20130315942A1 (en) 2013-11-28
US9115207B2 (en) 2015-08-25
CA3031126A1 (en) 2010-06-10
AU2009323523A1 (en) 2010-06-10
TWI539160B (zh) 2016-06-21
WO2010064430A1 (en) 2010-06-10
US20150315239A1 (en) 2015-11-05
EP3219720A3 (en) 2018-01-03
CN102307891A (zh) 2012-01-04
ES2913148T3 (es) 2022-05-31
EP3219720A2 (en) 2017-09-20
EP3219720B1 (en) 2022-03-09
CA3031126C (en) 2022-03-22
SG171977A1 (en) 2011-07-28
CN104650183B (zh) 2018-04-20
CN104650183A (zh) 2015-05-27
DK3219720T3 (da) 2022-05-09
IL212945B (en) 2018-03-29
MX2011005944A (es) 2011-07-28
IL212945A0 (en) 2011-07-31

Similar Documents

Publication Publication Date Title
RU2016146198A (ru) Терапевтические dll4-связывающие белки
NZ602119A (en) Peptide vaccines for cancers expressing tumor-associated antigens
UA110599C2 (uk) Пептид для імунотерапії пухлин, включаючи нейрональні пухлини та пухлини мозку
IN2014CN02050A (cg-RX-API-DMAC7.html)
EP3263585A3 (en) Foxm1 peptide and medicinal agent comprising the same
NZ600732A (en) Oxyntomodulin peptide analogue
UA103751C2 (ru) Иммуногенный пептид для иммунотерапии
ES2571879T3 (es) Moléculas de una sola cadena de TNFSF
NZ603813A (en) Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of histidyl-trna synthetases
ATE417065T1 (de) Hochaffiner ny-eso-t-zellen-rezeptor
RU2015103816A (ru) ПРОНИКАЮЩИЕ В КЛЕТКУ ПЕПТИДЫ, МИШЕНЬЮ КОТОРЫХ ЯВЛЯЕТСЯ eIF4E
NZ598932A (en) Identification of antigenic peptides from multiple myeloma cells
MX2009007261A (es) Vacuna de peptido foxp3.
NZ586074A (en) LCLRP peptides, constructs and uses thereof
NZ594481A (en) Truncated cystine-knot proteins
NZ596300A (en) Fviii-derived peptides
MX2010005816A (es) Epítopos de péptido de stat3.
CA2819463C (en) Tomm34 peptides and vaccines including the same
MX2011008917A (es) Peptidos vangl1 y vacunas que incluyen los mismos.
EP3868778A3 (en) Cdc45l peptides and vaccines including the same
NZ591133A (en) Novel melanoma antigen peptide and uses thereof
NZ592461A (en) Rab6kifl/kif20a epitope peptide and vaccines containing the same
WO2007029262A3 (en) Compositions and methods using same for the detection of viruses
NZ603379A (en) Ect2 peptides and vaccines including the same
MY151307A (en) Peptides having antimicrobial activity

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 03 DEC 2016 BY DENNEMEYER SA

Effective date: 20131115

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 DEC 2017 BY DENNEMEYER + CO

Effective date: 20161124

LAPS Patent lapsed